Forward-looking statements This press release may contain forward-looking statements regarding Can-Fite's expectations, beliefs or intentions in relation to, among other things, its product development efforts, its business and financial situation, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. This press release may contain forward-looking statements regarding Can-Fite's expectations, beliefs or intentions regarding, among other things, market risks and uncertainties and Can-Fite's ability to comply with all conditions prior to the closing of the proposed offering, its product development efforts, its business and financial situation, results of operations, strategies or prospects. Since the forward-looking statements refer to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite's actual results to differ materially from any future results expressed or implied by the forward-looking statements.
Can-Fite assumes no obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise. Because the forward-looking statements refer to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite's actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. This press release will not constitute an offer to sell or a request for an offer to buy any of the securities described here. These forward-looking statements may be included, among others, in various submissions submitted by Can-Fite to the United States.
Can-Fite assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by applicable securities law. Can-Fite's liver drug, Namodenoson, is being evaluated in a phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH), and enrollment in a phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, is expected to begin. Many factors could cause Can-Fite's actual activities or results to differ substantially from the activities and results expected in such forward-looking statements, including, but not limited to, the factors summarized in Can-Fite's filings with the SEC and in its regular filings with the TASE. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite's authorized executive officers.
Can-Fite's liver cancer drug, Namodenoson, is in phase II trials in patients with liver cancer and is due to enter phase II for the treatment of non-alcoholic steatohepatitis (NASH).
